Capricor Competitors

Stocks . USA . 
Stock . Capricor Therapeutics
CAPR Stock  USD 13.23  0.44  3.44%   
Capricor Therapeutics competes with Bio Path, NextCure, Pulmatrix, Akari Therapeutics, and Soleno Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Capricor Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Capricor Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Capricor Therapeutics Correlation with its peers.
To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Capricor Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
8.6113.2117.81
Details
Intrinsic
Valuation
LowRealHigh
11.9120.3624.96
Details

Capricor Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Capricor Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Capricor and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Capricor Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
UNCY
+ 0.59
NXTC
CDTX
+ 0.51
UNCY
AKTX
+ 0.44
BPTH
PHIO
+ 0.42
BPTH
PHIO
+ 0.36
AKTX
SLNO
+ 0.34
AKTX
  
High negative correlations   
PULM
- 0.62
NXTC
CDTX
- 0.58
BPTH
UNCY
- 0.47
PULM
PHIO
- 0.45
PULM
UNCY
- 0.44
BPTH
CDTX
- 0.32
SLNO

Risk-Adjusted Indicators

There is a big difference between Capricor Stock performing well and Capricor Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Capricor Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BPTH  10.57  0.40  0.00 (0.04) 0.00 
 0.00 
 29.81 
(15.56)
 189.05 
CBIO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
DFFN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
NXTC  3.31 (0.35) 0.00 (0.29) 0.00 
 0.00 
 6.49 
(6.76)
 18.95 
PULM  4.60  0.81  0.17  1.30  4.54 
(5.32)
 9.74 
(6.29)
 41.84 
AKTX  4.86  0.45  0.08  0.42  5.38 
(6.44)
 11.21 
(9.00)
 41.26 
SLNO  2.26  0.25  0.08  0.06  2.45 
(3.05)
 4.99 
(4.78)
 20.36 
UNCY  3.88 (0.06) 0.00 (0.17) 0.00 
 0.00 
 7.58 
(6.56)
 28.72 
CDTX  3.50  0.10  0.02  0.02  5.52 
(3.07)
 6.73 
(7.85)
 22.90 
PHIO  11.93  2.36  0.18  0.43  9.97 
(24.06)
 9.40 
(10.59)
 336.29 
All Fundamental Data

Capricor Therapeutics Competitive Analysis

The better you understand Capricor Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Capricor Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Capricor Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CAPR BPTH NXTC PULM AKTX SLNO UNCY CDTX PHIO MBRX
 3.44 
 13.23 
Capricor
 5.00 
 0.19 
Bio
 4.17 
 0.69 
NextCure
 3.55 
 8.46 
Pulmatrix
 18.68 
 1.08 
Akari
 0.63 
 49.34 
Soleno
 1.72 
 0.59 
Unicycive
 1.39 
 22.05 
Cidara
 3.01 
 1.29 
Phio
 2.59 
 1.13 
Moleculin
Market Volatility
(90 Days Market Risk)
Not too volatile
Out of control
Dangerous
Moderately volatile
Slightly risky
Very steady
Dangerous
Not too volatile
Very risky
Extremely Dangerous
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
OK
Insignificant
Weak
Very Weak
Very Weak
Insignificant
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
About Average
Dangerous
Very High
Quite High
Very High
Average
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Hold
Cautious Hold
Strong Sell
Hold
Hold
Buy
Hold
Strong Hold
Hold
Hold
Current Ratio
2.69
15.57
33.87
8.19
3.73
3.43
4.43
1.93
6.48
10.47
Net Asset
58.73 M
3.22 M
80.86 M
33.96 M
4.36 M
330.97 M
14.19 M
214.8 M
9.36 M
38.22 M
Profit Margin
-1.47
N/A
N/A
-0.97
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(23.01 M)
(15.76 M)
(54.34 M)
(13.27 M)
(16.8 M)
(182.44 M)
(30.18 M)
(176.1 M)
(10.64 M)
(29.5 M)
Operating Margin
-5.75
N/A
N/A
-7.26
N/A
N/A
N/A
-71.54
N/A
N/A
Current Valuation
510.91 M
531.06 K
(42.51 M)
19.06 M
22.79 M
2.01 B
28.9 M
58.67 M
(2.1 M)
4.91 M
Price To Book
8.71
2.34
0.31
2.73
3.07
9.17
2.17
1.5
1.28
1.86
Retained Earnings
(159.37 M)
(107.61 M)
(380.14 M)
(287.6 M)
(227.46 M)
(452.26 M)
(64.54 M)
(611.26 M)
(139.21 M)
(131.6 M)
Current Asset
22.4 M
9.59 M
46.99 M
8.34 M
69.66 M
N/A
N/A
108.22 M
9.23 M
28.09 K
Beta
4.11
0.05
0.71
1.66
0.95
-1.69
2.25
0.88
1.47
1.94
Number Of Employees
101
10
82
22
9
92
14
16
8
18
Shares Outstanding
45.47 M
5.77 M
28.01 M
3.65 M
20.65 M
45.86 M
103.8 M
10.95 M
860.72 K
12.01 M
Cash Flow From Operations
(25.6 M)
(11.54 M)
(40.8 M)
(15.98 M)
(16.43 M)
(69.1 M)
(18.28 M)
(176.53 M)
(10.75 M)
(24.1 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
2.24 M
113 K
5.15 M
8.76 M
4.58 M
3 M
811 K
3.58 M
35 K
574 K
Return On Equity
-1.03
-11.6
-0.58
-0.63
-12.81
-0.87
-1.47
-2.2
-1.27
-1.41
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.35
-1.94
-0.33
-0.19
-1.73
-0.45
-0.63
-0.4
-0.61
-0.57
Number Of Shares Shorted
8.16 M
79.35 K
59.22 K
38.64 K
77.71 K
4.54 M
795.15 K
181.99 K
45.46 K
2.2 M
Book Value Per Share
1.69
-0.19
2.7
2.99
-0.035
5.36
0.28
14.92
7.4
2.49
Current Liabilities
6.67 M
937 K
5.53 M
4.11 M
21.12 M
N/A
N/A
5.97 M
2.17 M
772.79 K
Total Asset
58.73 M
3.22 M
80.86 M
33.96 M
4.36 M
330.97 M
14.19 M
214.8 M
9.36 M
38.22 M
Debt To Equity
0.15
0.013
0.01
0.044
0.07
0.016
0.023
0.18
0.013
0.007
Short Ratio
8.02
0.43
0.75
0.92
1.92
11.8
1.4
2.38
0.5
0.08
Target Price
42.43
12.0
3.0
10.0
80.0
74.25
5.5
36.6
36.0
18.0
Shares Owned By Institutions
38.53
7.41
52.36
9.01
0.5
97.07
60.39
69.43
2.07
3.87
Market Capitalization
581.56 M
1.21 M
20.16 M
29.84 M
30.35 M
2.25 B
60.44 M
244.92 M
2.02 M
13.93 M
Price To Earning
42.39
-6.21
-25.44
-1.3
-2.15
-3.71
N/A
-2.21
-0.8
-3.81
Price To Earnings To Growth
N/A
N/A
0.03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
25.04
N/A
9.52
2.98
N/A
N/A
62.82
192.09
48.01
N/A
Net Income
(22.29 M)
(16.08 M)
(55.65 M)
(14.12 M)
(10.01 M)
(175.85 M)
(30.54 M)
(169.83 M)
(10.83 M)
(29.77 M)
Earnings Per Share
-1.02
-8.34
-1.99
-2.64
-2.58
-4.38
-0.46
-26.82
-14.81
-12.04
Shares Owned By Insiders
16.8
N/A
7.01
0.65
11.9
2.93
6.12
1.37
5.89
0.83
Revenue
25.18 M
N/A
N/A
7.3 M
N/A
N/A
675 K
1.27 M
N/A
N/A
Working Capital
19.59 M
1.14 M
62.23 M
16.93 M
1.77 M
275.14 M
(4.13 M)
161.18 M
7.69 M
19.46 M
Cash And Equivalents
51.42 M
17.02 M
185.49 M
42.91 M
8.15 M
24.07 M
10.57 M
53.08 M
18.02 M
58 M
Cash Per Share
2.11
2.38
6.68
12.67
0.14
2.97
0.7
0.74
1.32
2.03
Gross Profit
(22.13 M)
N/A
(54.2 M)
(671 K)
N/A
N/A
N/A
1.27 M
(7.01 M)
N/A
Day Typical Price
13.14
0.19
0.7
8.45
1.03
49.34
0.59
22.26
1.31
1.14
Accumulation Distribution
0.0448
0.27
0.0685
0.0575
0.14
0.0356
0.05
0.0291
0.0588
0.0513
Market Facilitation Index
0.6
0.06
0.05
0.5
0.15
1.79
0.03
0.66
0.08
0.06
Daily Balance Of Power
0.7333
(0.17)
(0.60)
0.58
1.133333
0.1732
0.3333
(0.47)
(0.50)
(0.50)
Period Momentum Indicator
0.44
(0.01)
(0.03)
0.29
0.17
0.31
0.01
(0.31)
(0.04)
(0.03)
Rate Of Daily Change
1.03
0.95
0.96
1.04
1.19
1.01
1.02
0.99
0.97
0.97
Day Median Price
13.1
0.19
0.71
8.45
1.01
49.33
0.59
22.37
1.32
1.14
Price Action Indicator
0.35
(0.01)
(0.03)
0.16
0.16
0.16
0.01
(0.47)
(0.05)
(0.03)
Coefficient Of Variation
19749.57
(13,170)
(780.08)
856.53
1849.06
3286.8
(3,086)
19483.11
2074.78
2549.41
Mean Deviation
3.43
10.57
3.31
4.6
4.86
2.26
3.88
3.5
11.93
11.43
Jensen Alpha
0.0841
0.4034
(0.35)
0.8135
0.4459
0.2497
(0.06)
0.1022
2.36
1.72
Total Risk Alpha
0.5841
2.82
(0.02)
1.57
1.2
0.5067
0.4563
0.6058
6.79
4.81
Sortino Ratio
0.0272
N/A
N/A
0.1659
0.0778
0.0798
N/A
0.0214
0.1776
0.1212
Downside Variance
20.13
N/A
N/A
26.86
35.45
6.28
N/A
33.16
125.22
106.33
Standard Deviation
4.56
24.07
4.25
6.51
6.74
3.32
5.02
4.72
39.18
29.33
Kurtosis
0.1761
16.21
0.5201
5.61
2.14
4.83
1.67
0.6419
52.19
39.09
Potential Upside
8.11
29.81
6.49
9.74
11.21
4.99
7.58
6.73
9.4
13.33
Treynor Ratio
0.0201
(0.04)
(0.29)
1.3
0.4221
0.0625
(0.17)
0.0177
0.4275
0.2153
Maximum Drawdown
22.77
189.05
18.95
41.84
41.26
20.36
28.72
22.9
336.29
223.29
Variance
20.79
579.56
18.03
42.43
45.4
11.02
25.23
22.31
1534.88
860.23
Market Risk Adjusted Performance
0.0301
(0.03)
(0.28)
1.31
0.4321
0.0725
(0.16)
0.0277
0.4375
0.2253
Risk Adjusted Performance
0.0125
0.003
(0.10)
0.1103
0.0558
0.0339
(0.02)
0.0126
0.0517
0.0439
Skewness
0.2636
2.77
0.2888
1.44
0.5415
1.43
0.7435
(0.52)
6.97
5.86
Semi Deviation
4.19
N/A
N/A
4.54
5.38
2.45
N/A
5.52
9.97
9.27
Information Ratio
0.0268
(0)
(0.10)
0.132
0.0688
0.0603
(0.01)
0.0261
0.0507
0.0426
Value At Risk
(6.46)
(15.56)
(6.76)
(6.29)
(9.00)
(4.78)
(6.56)
(7.85)
(10.59)
(17.65)
Expected Short fall
(3.76)
N/A
N/A
(5.32)
(6.44)
(3.05)
N/A
(3.07)
(24.06)
(18.22)
Downside Deviation
4.49
N/A
N/A
5.18
5.95
2.51
N/A
5.76
11.19
10.31
Semi Variance
17.59
N/A
N/A
20.59
29.0
6.0
N/A
30.48
99.42
85.91

Capricor Therapeutics Competition Performance Charts

Five steps to successful analysis of Capricor Therapeutics Competition

Capricor Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Capricor Therapeutics in relation to its competition. Capricor Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Capricor Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Capricor Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Capricor Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Capricor Therapeutics position

In addition to having Capricor Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Technology Thematic Idea Now

Technology
Technology Theme
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY